The 50-day moving average for DVAX moved above the 200-day moving average on November 27, 2024. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
The Momentum Indicator moved above the 0 level on December 17, 2024. You may want to consider a long position or call options on DVAX as a result. In of 85 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where DVAX advanced for three days, in of 274 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 199 cases where DVAX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
The 10-day RSI Indicator for DVAX moved out of overbought territory on November 15, 2024. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 26 similar instances where the indicator moved out of overbought territory. In of the 26 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 55 cases where DVAX's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for DVAX turned negative on November 18, 2024. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 48 similar instances when the indicator turned negative. In of the 48 cases the stock turned lower in the days that followed. This puts the odds of success at .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where DVAX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. DVAX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 91, placing this stock slightly better than average.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.641) is normal, around the industry mean (57.958). P/E Ratio (31.634) is within average values for comparable stocks, (89.727). DVAX's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.947). Dividend Yield (0.000) settles around the average of (0.122) among similar stocks. P/S Ratio (6.974) is also within normal values, averaging (19.472).
a developer of novel products to prevent and treat infectious diseases
Industry PharmaceuticalsOther
1 Day | |||
---|---|---|---|
MFs / NAME | Price $ | Chg $ | Chg % |
FPCGX | 30.91 | -0.26 | -0.83% |
Fort Pitt Capital Total Return | |||
NMPAX | 15.03 | -0.17 | -1.12% |
Columbia Mid Cap Index Inst | |||
JVMSX | 30.72 | -0.36 | -1.16% |
JHancock Disciplined Value Mid Cap R2 | |||
HWVZX | 12.79 | -0.17 | -1.31% |
Hotchkis & Wiley Sm Cp Divers Val Z | |||
KSDVX | 19.16 | -0.26 | -1.34% |
Keeley Small Cap Dividend Value A |
A.I.dvisor indicates that over the last year, DVAX has been loosely correlated with ACET. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if DVAX jumps, then ACET could also see price increases.
Ticker / NAME | Correlation To DVAX | 1D Price Change % | ||
---|---|---|---|---|
DVAX | 100% | +0.39% | ||
ACET - DVAX | 39% Loosely correlated | -0.75% | ||
SNDL - DVAX | 35% Loosely correlated | +4.17% | ||
SUPN - DVAX | 34% Loosely correlated | -0.74% | ||
AMPH - DVAX | 32% Poorly correlated | +0.02% | ||
IRWD - DVAX | 27% Poorly correlated | +2.32% | ||
More |